Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)

NCT01480258 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1315

Enrollment

INDUSTRY

Sponsor class

Conditions

Bacterial Infections
Virus Diseases

Interventions

BIOLOGICAL: PR5I
BIOLOGICAL: Rotavirus vaccine
BIOLOGICAL: Prevenar 13™
BIOLOGICAL: INFANRIX™ hexa

Sponsor

MCM Vaccines B.V.

Collaborators

[object Object]